Results for the year ended 30 June 2025

RNS Number : 8560J

Beximco Pharmaceuticals PLC

26 June 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Results for the year ended 30 June 2025

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its audited results for the year ended 30 June 2025.

Financial Highlights (consolidated)

Year ended 30 June 2025

· Net revenue increased 10.7% to Bangladesh Taka ("BDT") 49,120.4m / £295.6m (2023-24: BDT 44,391.7m / £286.6m

o Domestic sales increased 8.7% to BDT 45,046.9m / £271.1m (2023-24: BDT 41,433.2m / £267.5m)

o Export sales increased 37.7% to BDT 4,073.5m / £24.5m (2023-24: BDT 2,958.4m / £19.1m)

· Profit after tax increased 19.3% to BDT 6,998.9m / £42.1m (2023-24: BDT 5,866.8m / £37.9m)

· EPS for the year amounted to BDT 15.56 (2023-24: BDT 13.07)

· Recommended 47.5% cash dividend (BDT 4.75 per share)

The full year accounts can be viewed at the Company's website: www.beximcopharma.com. Once the Annual General Meeting (AGM) date has been confirmed, the Annual Report and Notice of AGM will be distributed to GDR and ordinary shareholders.

For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", dated 24 June 2026.

Exchange rates of £1=Taka 166.1585 for 2024-25 and £1=Taka 154.8989 for 2023-24 have been used in this announcement.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Sam Purewal / Lucy Molloy

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals PLC

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of financial position

As at 30 June 2025

	June 30, 2025	Amount in Taka June 30, 2024
ASSETS

Property, plant and equipment	43,541,872,125	42,487,710,980
Right-of-use assets	485,613,049	561,596,784
Intangible assets	4,694,133,629	4,720,696,879
Deferred tax asset	44,078,388	60,890,504
Goodwill	674,570,185	674,570,185
Other investments	20,974,134	20,973,372
Total Non-current assets	49,461,241,510	48,526,438,704

Inventories	13,586,475,819	12,118,129,675
Spares and supplies	799,643,860	896,665,035
Trade and other receivables	3,628,788,364	3,767,318,667
Loans, advances, deposits and prepayments	2,814,492,520	2,686,194,995
Advance income tax	356,507,571	295,169,915
Short term investment	900,000,000	200,000,000
Cash and cash equivalents	1,700,096,960	854,105,649
Total Current assets	23,786,005,094	20,817,583,936
TOTAL ASSETS	73,247,246,604	69,344,022,640

EQUITY AND LIABILITIES
Share capital	4,461,120,890	4,461,120,890
Share premium	5,269,474,690	5,269,474,690
Excess of issue price over face value of GDRs	1,689,636,958	1,689,636,958
Capital reserve on merger	294,950,950	294,950,950
Revaluation surplus	1,133,870,432	1,137,305,789
Unrealized gain/(loss)	18,148,958	18,148,196
Retained earnings	40,239,934,223	35,079,327,271
Total Shareholders' equity	53,107,137,101	47,949,964,744
Non-controlling interest	3,977,498,766	3,952,938,136

TOTAL EQUITY	57,084,635,867	51,902,902,880

Long term borrowings-net of current maturity	1,503,595,560	1,757,971,294
Liability for gratuity and WPPF	3,690,095,513	3,546,580,069
Deferred tax liability	2,575,780,261	2,574,582,041
Non-current liabilities	7,769,471,334	7,879,133,404

Short term borrowings	2,025,393,637	2,996,659,963
Long term borrowings-current maturity	1,436,751,660	1,270,799,475
Trade and other payables	2,925,993,801	3,671,371,549
Accrued expenses	1,174,096,256	1,106,664,942
Dividend payable	302,271,608	87,223,073
Income tax payable	528,632,441	429,267,354
Total Current liabilities	8,393,139,403	9,561,986,356
Total liabilities	16,162,610,737	17,441,119,760
TOTAL EQUITY AND LIABILITIES	73,247,246,604	69,344,022,640

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of profit or loss and other comprehensive income

For the year ended 30 June 2025

		Amount in Taka

	30 June 2025	30 June 2024

Net revenue	49,120,354,035	44,391,603,925
Cost of goods sold	(26,824,077,599)	(24,757,616,704)
Gross profit	22,296,276,436	19,633,987,221

General and administrative expenses	(1,401,982,177)	(1,309,760,618)
Selling, marketing and distribution expenses	(11,046,578,053)	(9,649,855,640)
Operating expenses	(12,448,560,230)	(10,959,616,258)
Profit from operations	9,847,716,206	8,674,370,963

Other income	608,998,701	394,587,584
Finance cost	(991,706,942)	(1,159,702,167)
Profit before tax and WPPF	9,465,007,965	7,909,256,380
Contribution to WPPF	(460,957,986)	(383,780,467)

Profit before tax	9,004,049,979	7,525,475,913
Current tax	(1,986,172,572)	(1,637,872,251)
Deferred tax	(19,007,698)	(20,832,192)
Income tax expenses	(2,005,180,270)	(1,658,704,443)
Profit after tax	6,998,869,709	5,866,771,470

Owners of the Company	6,940,622,589	5,829,529,200
Non-controlling interest	58,247,120	37,242,270
Profit/(loss) attributable	6,998,869,709	5,866,771,470
Other comprehensive income/(loss)	762	-
Total comprehensive income	6,998,870,471	5,866,771,470

Owners of the Company	6,940,623,351	5,829,529,200
Non-controlling interest	58,247,120	37,242,270
Total comprehensive income attributable	6,998,870,471	5,866,771,470

Earnings per share (EPS)	15.56	13.07

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of changes in equity

For the year ended 30 June 2025

Amount in Taka

	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the Company	Non-controlling interests	Total
Balance as on 01 July 2024	4,461,120,890	5,269,474,690	1,689,636,958	294,950,950	1,137,305,789	18,148,196	35,079,327,271	47,949,964,744	3,952,938,136	51,902,902,880

Total comprehensive income:
Profit for the year	-	-	-	-	-	-	6,940,622,589	6,940,622,589	58,247,120	6,998,869,709
Other comprehensive income/(loss)	-	-	-	-	-	762	-	762	-	762
Transactions with the shareholders:
Cash dividend	-	-	-	-	-	-	(1,784,448,356)	(1,784,448,356)	(33,686,490)	(1,818,134,846)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(4,432,719)	-	4,432,719	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	997,362	-	-	997,362	-	997,362
Balance as on 30 June 2025	4,461,120,890	5,269,474,690	1,689,636,958	294,950,950	1,133,870,432	18,148,958	40,239,934,223	53,107,137,101	3,977,498,766	57,084,635,867
Net asset value (NAV) per share							Tk.	119.04

For the year ended 30 June 2024

	Share capital	Share premium	Excess of issue price over face value of GDRs	Capital reserve on merger	Revaluation surplus	Unrealized gain/(loss)	Retained earnings	Equity attributable to owners of the Company	Non-controlling interests	Total
Balance as on 01 July 2023	4,461,120,890	5,269,474,690	1,689,636,958	294,950,950	1,141,177,755	18,148,196	30,806,194,299	43,680,703,738	3,938,962,240	47,619,665,978
Total comprehensive income:
Profit for the year	-	-	-	-	-	-	5,829,529,200	5,829,529,200	37,242,270	5,866,771,470
Transactions with the shareholders:
Cash dividend	-						(1,561,392,312)	(1,561,392,312)	(23,266,374)	(1,584,658,686)
Others:
Adjustment for depreciation on revalued assets	-	-	-	-	(4,996,084)	-	4,996,084	-	-	-
Adjustment for deferred tax on revalued assets	-	-	-	-	1,124,118	-	-	1,124,118	-	1,124,118
Balance as on 30 June 2024	4,461,120,890	5,269,474,690	1,689,636,958	294,950,950	1,137,305,789	18,148,196	35,079,327,271	47,949,964,744	3,952,938,136	51,902,902,880
Net asset value (NAV) per share							Tk.	107.48

Beximco Pharmaceuticals Limited and its Subsidiaries

Consolidated statement of cash flows

For the year ended 30 June 2025

	30 June 2025	Amount in Taka 30 June 2024
Cash flows from operating activities:

Cash receipts from customers and others	49,891,648,809	44,643,302,227
Cash paid to suppliers and employees	(39,742,461,113)	(33,402,026,973)
Cash generated from operations	10,149,187,696	11,241,275,254

Interest paid	(976,729,205)	(1,149,361,253)
Interest received	19,922,699	2,795,667
Income tax paid	(1,969,795,120)	(1,730,243,351)
Net cash generated from operating activities	7,222,586,070	8,364,466,317

Cash flows from investing activities:
Acquisition of property, plant and equipment	(2,781,313,389)	(1,993,729,774)
Intangible assets	(247,936,908)	(240,827,549)
Disposal of property, plant and equipment	60,327,928	26,956,352
Dividend received	974,510	1,142,364
Short term investment	(700,000,000)	(200,000,000)
Net cash used in investing activities	(3,667,947,859)	(2,406,458,607)

Cash flows from financing activities:

Net increase/(decrease) in long term borrowings	(152,518,998)	(1,049,462,507)
Net increase/(decrease) in short term borrowings	(971,266,326)	(3,624,510,308)
Dividend paid	(1,603,086,311)	(1,585,900,722)
Net cash from/(used in) financing activities	(2,726,871,635)	(6,259,873,537)
Increase/(decrease) in cash and cash equivalents	827,766,576	(301,865,827)
Opening cash and cash equivalents	854,105,649	1,135,686,178
Effect of exchange rate changes on cash and cash equivalents	18,224,735	20,285,298
Closing cash and cash equivalents	1,700,096,960	854,105,649

Net operating cash flows per share	16.19	18.75

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

FR FFFVLRIIEFIR

Date	26 Jun 2026
Time	07:00:03
Category	Results
ID	8560J

Date	26 Jun 2026
Time	07:00:03
Category	Results
ID	8560J

t

Company Information

AI Summary

RNS Metadata

Company Information

AI Summary

RNS Metadata

Results for the year ended 30 June 2025